{"id":"W3170518524","doi":"10.1200/jco.2021.39.15_suppl.4500","title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval","funders":"","keywords":"Medicine; Sunitinib; Interim analysis; Clinical endpoint; Renal cell carcinoma; Discontinuation; Internal medicine; Population; Temsirolimus; Randomization; Oncology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003787679,0.001249403,0.002310051,0.0005164187,0.000438957,0.001042041,0.001235471,0.001287167,0.003261019],"category_scores_gemma":[0.001745202,0.0006054821,0.002707486,0.0004725498,0.0007843737,0.001302079,0.0006015191,0.002944915,0.0009379957],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001224272,"about_ca_system_score_gemma":0.000967514,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009778654,"about_ca_topic_score_gemma":0.002506593,"domain_scores_codex":[0.9985556,0.0008123317,0.0000811377,0.0002119457,0.0001198862,0.0002191088],"domain_scores_gemma":[0.9984561,0.0002832123,0.0004214245,0.0001853332,0.00007238991,0.0005815342],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9382272,0.01772979,0.0037237,0.0003187931,0.001763575,0.0000468499,0.00009577817,0.001173211,0.005758371,0.00005212357,0.001060946,0.03004971],"study_design_scores_gemma":[0.3990994,0.5547101,0.0379351,0.0000371305,0.002225994,0.0001695482,0.00005459361,0.001413501,0.002834043,0.0001476696,0.001335913,0.00003694425],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944813,0.001947217,0.0003124012,0.0002013086,0.0001026162,0.0009023488,0.001029988,0.00005971068,0.0009631293],"genre_scores_gemma":[0.9947922,0.0008094813,0.0005059919,0.000299753,0.0001654885,0.000567597,0.00156081,0.00001602825,0.001282736],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003787679,"threshold_uncertainty_score":0.02003139,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1369349574767477,"score_gpt":0.4100780355737302,"score_spread":0.2731430780969825,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}